Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
The court confirmed the sale of $ 305 million to the non-profit level of the leadership of the 23Antme’s assets former CEO Anne Wojcicki, manages a bankrupt genetics company effectively.
Rejeeneron first received 23And for $ 256 million, but the Non-Commercial Ttam Research Institute was later full of $ 305 million for the company.
On sale, TTAM, all 23AndMe’s assets, as well as Private Genome service (PGS) and research services, as well as Lumonaid health work.
Wojcicki said: “I will be excited that the TTAM will be able to build, understand, understand, understand and extract it in a 23AND mission.
“In non-profit, TTAM will be the champion to improve our knowledge about DNA – the life code – the goodness of people, creating a source to develop human health in world health.”
23Andme once had about $ 6 billion in a market lid. However, in recent years, including in 2023, including a cyber violation Significant legal issuesAnd cash flows are worth $ 100 million as a dryer, the company has difficulties and challenges to express a business model that resulted in the cost of $ 100 million.
In January, it revealed that 23Andme Weighing future directions For the company, in addition to a sale as a reconstruction, asset sales and licensing. The notice was given a while notifying the results of the company’s weak Q3 for the 2025 fiscal year, the notification that would only $ 80 million.
As the company flies, the company of 23antme wojcicki has rejected many efforts to make it special. In March 2025 23AndMe was submitted for bankruptcy and Wojcicki resigned.
23Antme Chairman of the Board Mark Jensen said: “This approval strengthens the way to protect against the way to help a person tried in our proceedings and providing a greater understanding of life in our proceedings and ensure the benefits of life.
“The company is aimed at completing the steps needed to complete the operation in the next week, which is the company’s turn to the next chapter as non-profit.”
“Control of the former 23Andme CEO is” confirmed “and published for $ 305 million for non-profit” Medical device networkA global brand.
The information on this site has only been included in the faith for general information purposes. We are not intended to give advice for you to be careful and provide no representation or intended representation or intended representation or intended. You must receive professional or specialist recommendations before any action on the basis of our site.
